Introduction
============

Diffuse large B-cell lymphoma (DLBCL) is one of the most frequent subtypes of non-Hodgkin's lymphoma, accounting for \>25% of all newly diagnosed cases worldwide.[@b1-ott-9-3017] Despite substantial advance in treatment since the introduction of rituximab, the prognosis of DLBCL remains unsatisfactory due to its aggression with heterogeneous clinical behaviors.[@b2-ott-9-3017] A large number of studies have found multiple factors to predict the prognosis of patients with DLBCL. However, the hallmark prognostic factor is not fully confirmed in patients with DLBCL.

Systemic immune suppression is susceptible to the development of lymphoma.[@b3-ott-9-3017] Emerging evidence has shown a close association between the host immune status and lymphoma biology, indicating that the clinical outcomes of lymphoma are associated with tumor inflammation and immunology.[@b4-ott-9-3017] Tumor inflammation and immunology have been extensively identified to be involved in tumor biologic behaviors.[@b5-ott-9-3017],[@b6-ott-9-3017] Systemic inflammatory markers have also been reported to predict the survival outcomes in various solid cancers, such as C-reactive protein, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio.[@b7-ott-9-3017]--[@b9-ott-9-3017] Considering the cost and technical limitations for clinical application, increasing studies have focused on seeking a surrogate biomarker representing the host immune status in peripheral blood that can serve as a prognostic factor in DLBCL.[@b10-ott-9-3017],[@b11-ott-9-3017] Both lymphocytes and monocytes are surrogate biomarkers of immune response and tumor microenvironment; they have been extensively identified as the prognostic factors to predict survival for DLBCL.[@b12-ott-9-3017]

Recent data have suggested that the lymphocyte-to-monocyte ratio (LMR) may predict the survival outcomes of patients with DLBCL.[@b11-ott-9-3017] Some investigators reported that decreased LMR was linked to shorter survival in patients with DLBCL,[@b13-ott-9-3017],[@b14-ott-9-3017] while a few scientists suggested that decreased LMR had less association with prognosis in patients with germinal center-type DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).[@b15-ott-9-3017] Therefore, it is essential to further illuminate the prognostic performance of LMR in patients with DLBCL. In this study, we conducted an updated meta-analysis to evaluate the impact of LMR on the prognosis of 4,587 patients with DLBCL from eleven reports.

Methods
=======

Study search
------------

A literature review system with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines was used to search the published data.[@b16-ott-9-3017] The literature search was carried out in the databases of PubMed and Web of Science to evaluate the association of LMR with the clinical prognosis of patients with DLBCL (updated on October 20, 2015). The following keywords are used, including "lymphocyte-to-monocyte ratio", "lymphocyte monocyte ratio", "LMR", "diffuse large B cell lymphoma", "diffuse large B-cell lymphoma", "DLBCL", "prognostic", "survival", and "prognosis". Article language was restricted to English.

Study selection
---------------

Two investigators (HLS and YQP) reviewed all the candidate papers independently. Disagreements were resolved by discussion. Studies were included in the meta-analysis according to the following criteria: 1) investigated patients with DLBCL; 2) explored the association of LMR with overall survival (OS) or progression-free survival (PFS); 3) extracted available data of a hazard ratio (HR) with 95% CI for OS or PFS in multivariate analysis; and 4) article language restricted to English.

Data extraction
---------------

Two reviewers (HLS and YQP) reviewed each eligible study according to the inclusion criteria and extracted the available data. The extracted content included the first author's name, study country, study duration, tumor stage, cutoff value of decreased LMR, treatment method, study design, follow-up period, number of patients, and HRs with 95% CIs for OS and PFS in multivariate analysis.

Statistical analysis
--------------------

STATA software Version 11.0 (StataCorp LP, College Station, TX, USA) was used to analyze the extracted data. HRs with corresponding 95% CIs were directly obtained from each eligible study. Both the random-effects model (DerSimoian--Laird method) and the fixed-effects model (Mantel--Haenszel method) were used to generate the pooled results. Subgroup analysis and meta-regression were performed to explore the reasons for interstudy heterogeneity. Sensitivity analysis was conducted to estimate the stability of the combined results. The publication bias of the studies was evaluated by the Egger's linear regression test. Statistical analyses were two sided, and a *P*-value \<0.05 was considered statistically significant.

Results
=======

The selection and characteristics of the studies
------------------------------------------------

The flow chart of the study selection has been shown in [Figure 1](#f1-ott-9-3017){ref-type="fig"}. A total of 18 studies were recorded in the initial electronic search. According to the inclusion and exclusion criteria, there were eleven eligible studies included in this meta-analysis. The major characteristics of these studies are shown in [Table 1](#t1-ott-9-3017){ref-type="table"}. These included studies with 4,578 patients were mostly published between 2012 and 2015. There were six studies composed of two cohorts reporting the HR with 95% CI. One study included only late-stage disease (III/IV), whereas ten studies involved all the disease stages. Patients with DLBCL were treated with R-CHOP in eight studies, and patients in other studies were treated with various therapeutic approaches, including CHOP, radiation, and surgery marked as non-R-CHOP. Ten studies with 4,441 patients with DLBCL investigated the association of LMR with OS, while seven studies with 2,100 patients explored the correlation between LMR and PFS.

The association of LMR with OS in DLBCL
---------------------------------------

Ten studies reported the association of LMR with OS in 4,441 patients with DLBCL ([Table 2](#t2-ott-9-3017){ref-type="table"}). The pooled results of these studies indicated that patients with decreased LMR were significantly associated with shorter OS (HR =1.79, 95% CI =1.54--2.08, *P*\<0.001), and there was no significant heterogeneity among these studies (*P*~H~=0.212; [Figure 2](#f2-ott-9-3017){ref-type="fig"}). Thereafter, subgroup analysis was performed according to confounders, including the country of study, cutoff value defining decreased LMR, treatment method, and sample size.

In the stratified analysis by population-based country, we found that the pooled HRs were 1.59 (95% CI =1.31--1.94) for patients in Western countries and 2.08 (95% CI =1.65--2.63) for patients in Eastern countries. Stratification by cutoff showed that decreased LMR was associated with poor prognosis for patients with both LMR cutoff \<3 (HR =1.65, 95% CI =1.38--1.98) and ≥3 (HR =2.12, 95% CI =1.61--2.79). Subgroup analysis by treatment method suggested that there were similar HRs in patients treated with R-CHOP (HR =1.75, 95% CI =1.48--2.08) and non-R-CHOP (HR =1.90, 95% CI =1.38--2.61). Similar results were also observed in subgroup analysis by sample size (\<400 vs ≥400) ([Table 2](#t2-ott-9-3017){ref-type="table"}).

The association of LMR with PFS in DLBCL
----------------------------------------

The association of LMR with PFS in 2,100 patients with DLBCL was further investigated in this meta-analysis ([Table 2](#t2-ott-9-3017){ref-type="table"}). A total of seven studies presented the influence of LMR on PFS in patients with DLBCL. Combined data from these seven studies indicated that decreased LMR was obviously correlated with poor PFS (HR =2.21, 95% CI =1.80--2.72, *P*\<0.001), and there was no heterogeneity among these studies (*I*^2^=0.0%, *P*~H~=0.192; [Figure 3](#f3-ott-9-3017){ref-type="fig"}). Subsequently, stratified analysis was also conducted on the basis of the earlier confounders in PFS. Stratification showed that decreased LMR could predict poor prognosis in DLBCL regardless of the country of study (Western vs Eastern), cutoff (\<3 vs ≥3), treatment (R-CHOP vs non-R-CHOP), and sample size (\<400 vs ≥400) ([Table 2](#t2-ott-9-3017){ref-type="table"}).

Heterogeneity
-------------

In this meta-analysis, no significant heterogeneity among the studies was found for PFS (*P*~H~\<0.212) and OS (*P*~H~=0.192), and the fixed-effect model was used to assess OS and PFS. In addition, sensitivity analysis and publication bias were also carried out to further explore the potential heterogeneity and the stability of the results among studies for OS and PFS. The pooled HRs for OS ([Figure 4A](#f4-ott-9-3017){ref-type="fig"}) and PFS ([Figure 4B](#f4-ott-9-3017){ref-type="fig"}) were not significantly affected by removing a single study each time. Concurrently, publication bias was not observed for OS and PFS from the Begg's funnel plot ([Figure 5A and B](#f5-ott-9-3017){ref-type="fig"}) and Egger's test ([Table 2](#t2-ott-9-3017){ref-type="table"}).

Discussion
==========

This updated meta-analysis aims to explore the associations of decreased LMR with OS and PFS in patients with DLBCL. Our results combined the survival outcomes of 4,578 patients with DLBCL extracted from eleven individual studies, suggesting that patients with DLBCL with decreased LMR had shorter OS and PFS. Subgroup analysis stratified by the country of study, cutoff value defining decreased LMR, treatment method, and sample size did not attenuate the prognostic significance of LMR in DLBCL. Despite substantial progress in the knowledge of the correlations between inflammatory response markers and survival outcomes of various cancers, the influence of inflammatory markers on tumor prognosis remains inconsistent. A previous meta-analysis that combined nine studies has shown an increased risk with low LMR from a total of 4,198 individuals.[@b17-ott-9-3017] Our study is an updated meta-analysis covering a total of eleven published studies reporting the correlations between decreased LMR and the clinical prognosis in patients with DLBCL.

The link between inflammation and cancer has been extensively reported. Relevant mechanistic investigations also support the biologic and prognostic importance of tumor microenvironment with proinflammation in tumor progression.[@b5-ott-9-3017],[@b18-ott-9-3017] A decreased LMR represented a decreased lymphocyte count and/or an increased monocyte count, as well as lymphopenia. Lymphocytes play an important role in tumor immunological surveillance and defense by suppressing tumor cell growth and proliferation.[@b19-ott-9-3017] Chemokines (including CCL-2 or CCL-5 produced by tumor cells, fibroblasts, or immune cells) recruit monocytes in the tumor microenvironment. As soon as these cells encounter chemokines, tumor-associated macrophages are quickly differentiated from them and transform to a tumor-promoting M2-like macrophage polarization under certain conditions that depresses Th1-mediated inflammation through interleukin (IL)-10 and IL-1b production. Then tumor-promoting M2-like macrophage secretes different proangiogenic factors (such as vascular endothelial growth factor, IL-8, fibroblast growth factor, and matrix metalloproteinase 9) to induce angiogenesis. Therefore, LMR can present the status of pro-tumor and antitumor ability in response to inflammation, and its value combining with lymphocyte and monocyte counts index may reflect the protumor ability and antitumor capacity of the host more concisely. In addition, it is convenient and inexpensive to measure the parameter of LMR in clinical application, which makes it a fascinating marker for the prediction of DLBCL.

Recently, numerous studies have explored the prognostic significance of LMR in a variety of solid cancers, including gastric cancer,[@b9-ott-9-3017] lung cancer,[@b20-ott-9-3017] colorectal cancer,[@b21-ott-9-3017] and nasopharyngeal carcinoma.[@b22-ott-9-3017] However, few studies reported the prognostic value of LMR in DLBCL. Li et al[@b11-ott-9-3017] suggested that LMR was an effective prognostic factor in patients with DLBCL treated with R-CHOP. Koh et al[@b23-ott-9-3017] observed that patients with DLBCL with decreased LMR had obviously lower survival (OS and PFS) than those with elevated LMR. Wei et al[@b15-ott-9-3017] showed that decreased LMR was not associated with the survival outcomes in patients with germinal center-type DLBCL. Lin et al[@b17-ott-9-3017] reported that a low LMR at diagnosis had an adverse effect on outcome for patients with DLBCL according to the evidence from nine studies consisting of 4,198 subjects. Our study was an updated meta-analysis reporting the prognostic performance of LMR in patients with DLBCL, revealing that decreased LMR was used to assess clinical outcomes for patients with DLBCL, especially patients treated with R-CHOP. In addition, an advantage of LMR was that it is convenient to measure in routine testing at low cost. Therefore, LMR is a potential and promising marker for clinical application.

There are some limitations in our study. First, decreased LMR and the clinicopathologic characteristics of patients were not systematically analyzed, such as Ann-Arbor stage, bone marrow involvement, cell-of-origin subtype, and lactate dehydrogenase. Second, the number of eligible studies was relatively small. In the subgroup analyses, the studies included in each subgroup were quite few.

Conclusion
==========

Our results suggest that decreased LMR may be an adverse prognostic factor for patients with DLBCL, which could contribute in stratification of patients and determination of individual therapeutic plans. More large-scale and well-designed studies are warranted to better clarify the prognostic value of LMR in DLBCL.
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![Flow chart of the eligible studies in this meta-analysis.\
**Abbreviations:** HR, hazard ratio; OS, overall survival; PFS, progression-free survival.](ott-9-3017Fig1){#f1-ott-9-3017}

![Forest plots of the studies assessing the HRs with corresponding 95% CIs of LMR for OS.\
**Abbreviations:** HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; OS, overall survival; CI, confidence interval.](ott-9-3017Fig2){#f2-ott-9-3017}

![Forest plots of the studies estimating the HRs with corresponding 95% CIs of LMR for PFS.\
**Abbreviations:** HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; PFS, progression-free survival; CI, confidence interval.](ott-9-3017Fig3){#f3-ott-9-3017}

![Sensitivity analysis of the effect of individual studies on the pooled HRs for (**A**) OS and (**B**) PFS in DLBCL.\
**Abbreviations:** HR, hazard ratio; OS, overall survival; PFS, progression-free survival; DLBCL, diffuse large B-cell lymphoma.](ott-9-3017Fig4){#f4-ott-9-3017}

![Begg's funnel plots for the Egger's test evaluating the publication bias for (**A**) OS and (**B**) PFS.\
**Abbreviations:** OS, overall survival; PFS, progression-free survival; HR, hazard ratio; SE, standard error.](ott-9-3017Fig5){#f5-ott-9-3017}

###### 

The characteristics of the included studies

  First author                      Country                      Duration     Stage      Cutoff[a](#tfn1-ott-9-3017){ref-type="table-fn"}   Treatment       Design   Follow-up      No of patients   OS,[b](#tfn2-ott-9-3017){ref-type="table-fn"} HR (95% CI)   PFS,[b](#tfn2-ott-9-3017){ref-type="table-fn"} HR (95% CI)
  --------------------------------- ---------------------------- ------------ ---------- -------------------------------------------------- --------------- -------- -------------- ---------------- ----------------------------------------------------------- ------------------------------------------------------------
  Li et al[@b11-ott-9-3017]         People's Republic of China   2002--2009   I--IV      2.6                                                R-CHOP          R        NR             438              3.11 (1.24--7.81)                                           2.76 (1.30--5.85)
  Watanabe et al[@b14-ott-9-3017]   Japan                        2003--2009   I--IV      4                                                  R-CHOP          R        58             362              2.51 (1.26--5.01)                                           2.06 (1.25--3.41)
  Rambaldi et al[@b24-ott-9-3017]   Italy                        1984--2012   III + IV   2.6                                                CT + RT         R        77 (2--330)    1,057            1.88 (1.32--2.70)                                           --
  Koh et al[@b23-ott-9-3017]        Korea                        2004--2013   I--IV      3.04                                               R-CHOP          R        37 (1--131)    603              1.66 (1.18--2.34)                                           1.99 (1.47--2.68)
  Wei et al[@b15-ott-9-3017]        People's Republic of China   2001--2011   I--IV      2.6                                                CT + S          R        52 (1--133)    168              1.98 (0.98--3.99)                                           2.92 (0.99--8.61)
  Tadmor et al[@b25-ott-9-3017]     Serbia                       2004--2012   I--IV      2.8                                                R-CHOP          R        34             222              1.515 (1.00--2.29)                                          --
  Markovic et al[@b26-ott-9-3017]   Israel, Italy                1993--2010   I--IV      2.1                                                R-CHOP          R        NR             1,017            1.49 (1.07--2.06)                                           --
  Li et al[@b13-ott-9-3017]         People's Republic of China   2001--2011   I--IV      3.8                                                RT + CT         R        36             244              3.95 (2.17--7.20)                                           4.07 (2.24--7.39)
  Ho et al[@b27-ott-9-3017]         Taiwan                       2001--2010   I--IV      2.11                                               R-CHOP          R        53.28          148              1.53 (0.75--3.11)                                           1.40 (0.75--2.59)
  Jelicic et al[@b28-ott-9-3017]    Serbia                       2005--2013   I--IV      2.8                                                R-CHOP, R-CVP   R        NR             182              1.37 (0.711--2.63)                                          --
  Belotti et al[@b29-ott-9-3017]    Italy                        2007--2013   I--IV      2.4                                                R-CHOP          R        24 (7.2--61)   137              --                                                          8.00 (0.98--66.67)

**Notes:**

Result of multivariate analysis based on a reference more than its cutoff value.

Multivariate analysis. Stage: Ann Arbor stage.

**Abbreviations:** OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, retrospective; NR, not reported; CT, chemotherapy; RT, radio therapy; S, surgery; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisolone; HR, hazard ratio; CI, confidence interval.

###### 

The main results of the meta-analysis

  Outcome               Variables   No of studies   No of patients   *P*-value   Regression model, HR (95% CI)                                             
  --------------------- ----------- --------------- ---------------- ----------- ------------------------------- -------------------- -------------------- -------------------
  OS                    All         10              4,441            0.212       \<0.001                         0.145                1.83 (1.52--2.19)    1.79 (1.54--2.08)
  Stratified analysis                                                                                                                                      
  Country                                           0.086                                                                                                  
   Eastern              6           1,963           0.166            \<0.001                                     2.21 (1.61--3.02)    2.08 (1.65--2.63)    
   Western              4           2,478           0.740            \<0.001                                     1.59 (1.31--1.94)    1.59 (1.31--1.94)    
  Cutoff                                            0.139                                                                                                  
   \<3                  7           3,232           0.745            \<0.001                                     1.65 (1.38--1.98)    1.65 (1.38--1.98)    
   ≥3                   3           1,209           0.042            \<0.001                                     2.44 (1.41--4.22)    2.12 (1.61--2.79)    
  Treatment                                         0.662                                                                                                  
   R-CHOP               8           3,216           0.107            \<0.001                                     1.84 (1.45--2.34)    1.75 (1.48--2.08)    
   Non-CHOP             2           1,225           0.897            \<0.001                                     1.90 (1.38--2.61)    1.90 (1.38--2.61)    
  Sample size                                       0.453                                                                                                  
   \<400                6           1,326           0.115            \<0.001                                     1.97 (1.41--2.74)    1.92 (1.51--2.44)    
   ≥400                 4           3,115           0.458            \<0.001                                     1.70 (1.41--2.07)    1.70 (1.41--2.07)    
  PFS                   All         7               2,100            0.192       \<0.001                         0.226                2.31 (1.74--3.06)    2.21 (1.80--2.72)
  Stratified analysis                                                                                                                                      
  Country                                           0.230                                                                                                  
   Eastern              6           1,963           0.649            \<0.001                                     2.25 (1.71--2.97)    2.18 (1.77--2.69)    
   Western              1           137             --               0.053                                       8.00 (0.97--65.98)   8.00 (0.97--65.98)   
  Cutoff                                            0.787                                                                                                  
   \<3                  4           891             0.254            0.001                                       2.24 (1.31--3.82)    2.10 (1.37--3.21)    
   ≥3                   3           1,209           0.103            \<0.001                                     2.41 (1.62--3.58)    2.24 (1.77--2.84)    
  Treatment                                         0.606                                                                                                  
   R-CHOP               6           1,932           0.134            \<0.001                                     2.29 (1.68--3.13)    2.19 (1.77--2.70)    
   Non-CHOP             1           168             --               0.052                                       2.92 (0.99--8.61)    2.92 (0.99--8.61)    
  Sample size                                       0.534                                                                                                  
   \<400                5           1,059           0.104            \<0.001                                     2.49 (1.55--3.99)    2.37 (1.74--3.23)    
   ≥400                 2           1,041           0.429            \<0.001                                     2.08 (1.58--2.75)    2.08 (1.57--2.75)    

**Notes:** *P*~E~, *P*-value for Egger's test; *P*~H~, *P*-value for heterogeneity; *P*~Z~, *P*-value for *Z* test.

**Abbreviations:** OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; HR, hazard ratio; CI, confidence interval.
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